Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Breast Neoplasms 13cyclopia sequence 7Neoplasms 6Multiple Myeloma 6Fatigue 6Neoplasms, Plasma Cell 5Neoplasm Metastasis 4Lung Neoplasms 4Dyspnea 4Carcinoma, Non-Small-Cell Lung 4Anxiety Disorders 4Uterine Cervical Neoplasms 3Tobacco Use Cessation 3Prostatic Neoplasms 3Primary Myelofibrosis 3Leukemia 3Head and Neck Neoplasms 3Depression 3Carcinoma, Renal Cell 3Vomiting 2Smoking Cessation 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Parasomnias 2Pancreatic Neoplasms 2Pain 2Osteosarcoma 2Kidney Neoplasms 2Hodgkin Disease 2Hematologic Neoplasms 2

Interventions

11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2Surveys and Questionnaires 1ON 01910 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Splenomegaly × Surveys and Questionnaires × Clear all
NCT02730884 2020-08-07

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 6 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Splenomegaly, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡